Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin for Prevention of Type 1 Diabetes in High-Risk Children
NCT00223613Phase 3Unknown
- Sponsor
- University of Turku
- Start
- Aug 1997
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Generex Oral-lyn in type 1 diabetes mellitus (T1D) (2 arms), sponsored by University of Turku. Primary endpoint: Development of clinical type 1 diabetes. Status: unknown.
02
Drugs
Generex Oral-lyn
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00223613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00223613.